Condition: Basedow Disease · Sponsor: Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Describe the progression of inflammatory orbitopathy and the biological progression of patients receiving second-line treatment (immunosuppressants, radiotherapy, or biotherapy).
This description comes directly from the study's public registry record.
Boris BIENVENU, DR · 0140021738 · bbienvenu@15-20.fr
Always discuss trial participation with your own doctor first.
| Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts | Paris, paris, France | Recruiting |
| CHU Caen Normandie COTE DE NACRE | Caen, France | Recruiting |
| CHU Lyon - Hospices Civils de Lyon | Lyon, France | Recruiting |
| Hopital Saint Joseph | Marseille, France | Recruiting |
| CHU de Montpellier | Montpellier, France | Recruiting |
| CHU Nîmes | Nîmes, France | Recruiting |
| Hopital Fondation de Rothschild | Paris, France | Recruiting |
| CHU de Pontchaillou | Rennes, France | Recruiting |
| Hopital Civil / Nouvel Hopital Civil | Strasbourg, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07117981